Dc-Cik
Bladder Cancer
Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusCell therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 73/ 100
Competitive context
121 Active assets in the Bladder Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II G1 Therapeutics, Inc. | Phase 3 | BBB |
TRASTUZUMAB NKGen Biotech, Inc. | Phase 2 | BB |
Carboplatin G1 Therapeutics, Inc. | Phase 3 | BB |
Pembrolizumab Essen Biotech | Phase 3 | BB |
Cyclophosphamide Beijing Biotech | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Dc-Cik is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →